In this edition of DocTalk, Mary Rooney, PhD, clinical psychologist and chief of the Child and Adolescent Psychosocial Interventions Research Program at the National Institute of Mental Health (NIMH), explained how telehealth transformed ADHD care in 2020 and what the major concerns are moving forward for this patient population. [Podcast]

Hypertensive disorders of pregnancy (HDP) are associated with modestly increased risks for autism spectrum disorders (ASDs) and possibly attention-deficit/hyperactivity disorder (ADHD) in offspring, according to a study published online March 22 in JAMA Pediatrics.

The high co-occurrence rates of bipolar disorder (BD) and attention/deficit-hyperactivity disorder (ADHD) indicate clinicians need to routinely carry out screenings for adults with either condition, according to a meta-analysis published online in Neuroscience & Biobehavioral Reviews…In part 2 of this Q&A series, lead author Carmen Schiweck, PhD, Goethe University Frankfurt, Germany, discusses the surprising outcomes,…

Attention-deficit/hyperactivity disorder (ADHD) is a common neurological condition that affects more than 6.1 million people in the U.S…In this article, we’ll explore what the current literature says about the relationship between ADHD and sugar, and what treatment options are available for symptoms.

Attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) share some overlapping symptoms, and they can have similar effects on the way people function at school and on the job…It’s also possible to be misdiagnosed — one condition mistaken for the other. Here’s a look at what ADHD and OCD have in common, along with…

Timothy Wilens, MD, a child and adolescent psychiatrist at Massachusetts General Hospital in Boston, Massachusetts, led a discussion regarding the multidisciplinary management of ADHD, the diagnostic and treatment obstacles during the coronavirus disease 19 (COVID-19) pandemic, and the effect of medication abuse. This article recaps the key clinical pearls and takeaways from the conversation.

Atomoxetine, a selective norepinephrine reuptake inhibitor (SNRI), may improve outcomes for patients with both attention-deficit/hyperactivity disorder (ADHD) and posttraumatic stress disorder (PTSD), new research suggests. A pilot trial of veterans with comorbid ADHD/PTSD showed that atomoxetine significantly reduced ADHD symptoms and moderately improved PTSD treatment outcomes and quality of life in comparison with placebo.

Andrew J. Cutler, MD: There are several types of attention deficit hyperactivity disorder, or ADHD…Based on my clinical experience, ADHD is not a uniform disorder. It has many clinical presentations. It’s a very heterogeneous disorder clinically, as far as the way it presents—the pattern of symptoms.

A report revealing the “huge financial cost” of attention deficit hyperactivity disorder (ADHD) in Australia is calling for more resources and funding for parents who are struggling with the challenges of supporting their children…ADHD Australia conducted the largest survey of its kind last year, and for the 1,616 people it asked, there were three key…

Less green space surrounding a child’s home may be associated with a higher risk of developing attention-deficit/hyperactivity disorder (ADHD), according to a study published online in Environmental Health Perspectives…This study, based in Denmark, investigated associations between residential green space in early childhood with an ADHD diagnosis from age 5 on.

The COVID-19 pandemic has been contrasted against the 1918 Spanish Flu pandemic in many ways—some with reason, some without. But a comparison to last century’s pandemic could forecast an increase in new onset attention deficit/hyperactivity disorder (ADHD) cases over the coming years.

People with disabilities and disability advocates have pushed for remote work options for years. But many found that many employers weren’t amenable until the COVID-19 pandemic forced the issue.